PTC Therapeutics financials at a glance

+ Portfolio

The revenue of PTC Therapeutics is reported as 0.93782 billion Dollars in the fiscal year 2023. The earnings were -5.63 Dollars per share in 2023, which was 23.4 higher than 2022. And about -0.18686 billion Dollars are reported as free cash flow in the financials of PTC Therapeutics 2023. No dividends were paid to the shareholders of the PTC Therapeutics stock NasdaqGS:PTCT in the financial year 2023.

$937.82M

Revenue

$-5.63

Earnings Per Share

21.94%

Gross Margin %

$-,121.00M

Free Cash Flow

Revenue

937.82

Earnings Per Share

-5.63

Gross Margin %

21.94

Free Cash Flow

-,121.00

Financials

Year	Year	TTM	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Rev.	Revenue	N/A	$937.82M	$698.80M	$538.59M	$380.77M	$306.98M	$264.73M	$194.39M	$82.71M	$36.77M	$25.25M	$34.70M
GM %	Gross Margin %	2.13%	21.94%	0.38%	-6.39%	-16.34%	12.18%	30.25%	37.22%	-42.23%	-,231.33%	-,216.25%	-58.16%
OM	Operating Margin	-64.29%	-37.26%	-62.95%	-69.62%	-90.23%	-62.80%	-35.75%	-33.07%	-,159.67%	0.00%	0.00%	-,130.85%
EPS	Earnings Per Share	$-8.66	$-5.63	$-7.35	$-7.43	$-5.04	$-4.27	$-2.33	$-2.02	$-4.17	$-5.07	$-2.97	$-5.17
Div.	Dividends	N/A	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
PR %	Payout Ratio %	0	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%
Sha.	Shares	N/AM	76.61M	73.82M	71.36M	70.32M	62.63M	58.4M	41.8M	34.56M	34.27M	33.69M	23.8M
OCF	Operating Cash Flow	N/A	$-,158.42M	$-,356.65M	$-,251.33M	$-,194.07M	$-98.64M	$-27.64M	$-10.06M	$-,103.57M	$-,124.34M	$-57.27M	$-46.92M
FCF	Free Cash Flow	N/A	$-,121.00M	$-,388.67M	$-,279.55M	$-,211.91M	$-,112.40M	$-34.74M	$-13.16M	$-,105.34M	$-,127.06M	$-61.94M	$-47.77M
FCFS	Free Cash Flow Per Share	$-4.63	$-3.73	$-7.10	$-4.78	$-3.79	$-2.45	$-0.93	$-2.31	$-3.09	$-3.78	$-1.96	$-3.72

PTC Therapeutics financials at a glance

Financials

Discover